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Perivascular stem cells (PSCs) include pericytes and adventitial cells. PSCs present 
multiple properties. PSCs are involved in angiogenesis, immunoregulation, and 
haematopoiesis support and are multi-lineage progenitor cells. Therefore, PSCs are a 
heterogeneous group of cells. We investigated PSC subsets based on novel markers: 
CD10 and CD107a. We analysed whether the expression of CD10 or CD107a on 
PSCs from foetal muscle correlates with the capability of differentiation and 
fibroblast-colony forming unit (CFU-f) content. The CD10-positive or CD107a-
positive PSCs were separated from CD10-negative or CD107a-negative PSCs by cell 
sorting. CFU-f was quantified. The differentiation of PSC subsets in culture was 
documented by cytochemistry. We confirmed that CD10 and CD107a PSCs subsets 
exist in multiple human tissues. CD10-positive and CD10-negative PSC subsets 
show similar ability for both CFU-f potential and osteogenesis in vitro.CD107a-
negative cells show higher CFU-f potential. However, CD107a-positive PSCs were 
associated with a higher osteogenic differentiation potential in human foetal muscle 
in vitro. Our study provides early evidence that CD107a-positive adventitial cells 
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In all organs, stem cells exist, attached to blood vessels. Recently, these stem cells 
have been isolated and shown to have the ability to regenerate tissue damaged by 
injury or disease, including bone, muscle, and even the heart. These blood vessel-
associated stem cells are not, however, all the same: some – probably a minority – 
have a much stronger potential for organ repair. One of the main projects of our 
laboratory – and the principal aim of my master’s thesis – is to identify and purify 
these high-potential stem cells, which will be much more efficient to regenerate 
organs in patients.  
To achieve this goal, I have 1) identified different subsets of blood vessel-associated 
stem cells with respect to the presence, at their surface, of a particular molecule 
produced by the cell itself; 2) purified these stem cell subsets based on the presence 
of these specific molecules. To this end, we use a complex machine called a 
fluorescence activated cell sorter (FACS); and 3) tested the ability of these different 
subsets of purified stem cells to regenerate tissues. I have worked principally on two 
of these molecules present at the cell surface and shown that blood vessel-associated 
stem cells, whether or not they possess these molecules, exhibit distinct potentials, 
notably for bone repair.  
These results support the validity of our approach and represent a step toward the 
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Chapter I: Introduction 
1.1 Definition of perivascular stem cells 
Perivascular stem cells (PSCs) consist of pericytes and adventitial stem cells. Pericytes 
ensheath capillaries and microvessels, while adventitial stem cells surround larger 
arteries and veins. Both cells can be reprogrammed into regenerative cells. In culture, 
PSCs give rise to mesenchymal stem cells (MSCs).  
1.2 Pericytes and adventitial cells: an introduction 
Pericytes were originally discovered by Charles-Marie Benjamin Rouget and were 
known as Rouget cells [1].  They were also referred to as mural cells because of their 
contractile fibres. In 1923, Zimmermann discovered the variation in the distribution 
of pericytes around blood vessels [2]. Zimmermann renamed them as pericytes. They 
are located abluminal to the endothelial cells and luminal to the parenchymal cells. 
They also play a vital role in the post capillary venules and cellular constituents of 
the capillaries. Pericytes are located in the capillaries, precapillary arterioles and 
postcapillary venules of the brain. Elements of the basal lamina are deposited and 
vascular components surround them completely [2,43].  
Pericytes play an important role in the stabilisation of blood vessels. They are also 
involved in the vascular development and maturation [3-8]. Pericytes are derived 
from multiple organs, involved in homeostasis, and implicated in several diseases. 
Recent evidence suggests that PSCs display multiple properties in terms of tissue 
development and regeneration. 
Pericytes are present in the basement membrane, they use direct as well as physical 
contact to intact with the blood vessels of the body. Pericytes help the brain in 
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performing homeostatic functions. They play an important role in the neurovascular 
unit.  The main functions of the pericyte is to regulate blood flow in the capillaries, 
clear the debris present in the cells and the permeability of the blood–brain barrier. 
The density of the pericytes varies with respect to the blood vessels and organs in 
which they are found. They can be found abundantly in the arterioles and small 
venules but are rarely found on the capillaries. The pericytes are most dense in 
vessels of the neural tissues of the body like the brain and the retina [3,42]. This is 
because the endothelial cells in the brain form a continuous endothelium with 
complex, tight junctions. They also interact with various pericytes and astrocytic 
pedicels to create the blood-brain barrier. The blood-brain barrier protects the brain 
cells from toxic blood-derived factors. The blood-brain barrier regulates the flow of 
essential components, nutrients, proteins, chemical substances, and other microscopic 
organisms between the bloodstream and the parenchymal tissue[6,42] 
The functioning of the pericytes is not clear because of different definitions of 
pericytes .  The deficiency of pericytes leads to the breakdown of the blood-brain 
barrier of the central nervous system [39]. Pericytes mainly work on the stabilization 
and hemodynamic processes of blood vessels. They can sense angiogenic stimuli, 
guide sprouting tubes, elicit endothelial survival functions, and even exhibit 
macrophage-like activities[6,40]. 
All the members of our group have documented that PSCs are multi-lineage 
progenitor cells [3, 5]. Moreover, subsets of PSCs have been identified as ancestors 
of mesenchymal stem cells (MSCs), and these subsets express MSC markers 
(CD105, CD90, CD73, CD44) and differentiate into adipocytes, osteoblasts, and 
chondrocytes. Reports from the study conducted in this field  show that PSCs could 
support hematopoietic stem cells as “niche cells” with endothelial cells [9-10]. 
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Chien-wen Chen et al. also pointed out that PSCs can regenerate the ischemic heart 
[11]. The result of another study has shown that perivascular stem cells are involved 
in the process of myofibroblast development in the liver [12]. Therefore, it is 
essential to identify and document the functions of pericytes. 
Adventitial cells located in the tunica adventitial of blood vessels can be 
differentiated into smooth muscle cells, endothelial-like cells, and mesodermal cells 
[13-14]. Adventitial progenitor cells express Sca1+ and CD34 but not CD31 [15]. 
Bruno Péault et al. purified and identified adventitial cells by adipose tissue cell 
sorting [16]; the study also showed that adventitial stromal cells can give rise to 
mesenchymal stem cells in vitro. The typical phenotype of adventitial stromal cells is 
CD34+CD31-CD146-CD45-, which is distinct from pericytes (CD146+CD31-CD34-
CD45-). Bruno Péault et al identified fresh adventitial cells derived from adipose 
express typical mesenchymal stem cells marker CD90, CD105, CD44 and CD73 and 
differentiated into mesodermal cells [16]. On the basis of complicated roles of 
adventitial cells and pericytes in the process of diseases. Therefore, it is essential to 
clarify the different functions of adventitial cells and pericytes to be used for distinct 
clinical applications.  
1.3 “Nature” of mesenchymal stem cells (MSCs) 
The mesenchymal stem cell can be applied to the regeneration field, considering that 
MSCs show multiple properties, including repairing damaged organs such as the 
heart, muscles, and bones; immunomodulatory activity; and proliferation ability [17-
18]. Mesenchymal stem cells (MSC) are stem cells present in many tissues. They are 
present in the bone marrow, fat tissue and in the umbilical cord. They renew on their 
own into multiple tissues like fat cells, bone, muscle and fat cells and connective 
4 
 
tissues.   However, because MSCs are heterogeneous group, it is necessary to 
understand their native nature and anatomical location in the body. Recently, a study 
has shown that subsets of perivascular stem cells derived from multiple human 
tissues give rise to typical mesenchymal stem cell markers (CD44, CD73, CD105, 
CD90, and CD10) and present MSC multipotency, including osteogenesis, 
adipogenesis, and chondrogenes[5], suggesting that subsets of perivascular stem cells 
are the progenitors of MSCs. Mesenchymal stem cells can produce more than one 
type of specialized cell in the body. They are a subset of multipotent precursors 
present in the stromal fraction of adult tissues. They multiply in long-term cultures of 
total cells from the bone marrow or other organs.  
1.4 CD10 and CD107a 
CD10 is known as membrane metallo-endopeptidase (MME), neutral endopeptidase, 
or neprilysin. The two main functions of CD10 are extracellular enzymatic activity 
and intracellular signalling pathways [19]. It is widely expressed in many human 
tissues,  lungs, intestine, uterus, as well as many other organs [19]. CD10 is a 
biomarker of cancer with stem cell features and is involved in the progression of 
prostate, breast, and  cancers to other organs of the body[20-22]. CD10 is well known 
as a marker of hematopoietic progenitor cells [23]. A study has also shown that 
CD10 plays a niche role to maintain the progenitor and stem cell pools in the 
mammary lineage [24]. CD10 also plays a significant role in haematological 
diagnosis. Recently, Sanna et al. reported that CD10 is an immunochemical marker 
of MSCs in the development of the kidneys [25]. Furthermore, there are evidences 
that CD10 expression is significantly increased during MSC differentiation into 
osteocytes and adipocytes [26]. However, another study has shown that there is no 
obvious difference in the level of CD10 expression during synovial-derived MSC 
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differentiation into chondrocytes [27]. Neprilysin is allied with many biochemical 
processes and it can be highly expressed in lung and kidney tissues.  There are 
observations that Neprilysin is associated with cancers to many organs of the body.  
CD107a is also known as lysosomal-associated membrane protein-1(LAMP). It is 
widely expressed in the endosome-lysosome membranes of cells. It is a protein in the 
body that is encoded by the LAMP-1 gene. It resides mainly on the membranes of the 
lysosomes. CD107a has a variety of cellular functions in the immune response and in 
cancer metastasis [28].Paper shows the level of LAMP was reduced by increasing 
cysteine cathepsin expression and activity. Furthermore, the paper also shows LAMP 
can protect cells from lysosomal cell death pathways [41].CD107a is expressed in 
tumour stem cells [29]. The proliferation of human bone marrow mesenchymal stem 
cells was reduced by blocking the LAMP-1 receptor, suggesting that LAMP-1 is 
involved in MAPK-ERK signalling to influence the proliferation of MSCs [30]. 
LAMP-1 is also associated with the stemness of neural stem cells [31]. On the basis 
of above functions of LAMP-1, it is necessary to further study the functions of 
CD107a in PSC. 
1.5 Aim and hypothesis of this project 
This project focuses on subsets of perivascular stem cells identified with two novel 
markers: CD10 and CD107a, detected with the Lyoplate® array system. 
In view of the above studies, the hypothesis of this project is that there are distinct 
functional subsets of PSCs. The aim of the study is to perform the following:  1) 
Documentation of the project and quantification of marker expression on PSCs by flow 
cytometry and immunohistochemistry; 2) Purification of the subsets of PSCs by cell 
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Chapter II: Methodology and Materials 
2.1 Human tissue 
Human foetal tissue samples were procured after elective surgical abortion (PMI 4-
48 h). The human foetal tissue samples and adult fat samples were permitted to be 
studied with the full permission of the NHS Lothian Research Ethics Committee 
(REC 08/S1101/1). 
The following specimens were obtained for research purposes: 11 foetal skeletal 
muscle specimens, one foetal brain specimen, one placenta specimen, and one adult 
fat tissue specimen. All specimens were analysed by flow cytometry. Each 
experiment included seven foetal skeletal muscle specimens, four used in CD10 PSC 
subset experiments and three used in CD107a PSC subset experiments. 
2.2 Flow cytometry and cell sorting 
Fresh skeletal muscle tissues were cut into small pieces in Dulbecco’s modified 
Eagle’s medium (DMEM, GIBCO) containing 20% foetal calf serum (FCS, GIBCO), 
1% penicillin-streptomycin (PS, GIBCO), and collagenases I, II, and IV (1 mg/mL, 
Sigma) and then incubated at 37℃ and 120rpm for 60 minutes in a water bath shaker. 
Cells were centrifuged and re-suspended in PBS with 2% FCS and then passed through 
100µm and 70µm cell strainers, centrifuged, and re-suspended in erythrocyte lysis 
buffer and incubated for 10 minutes at room temperature. The cells were then 
centrifuged again and passed through a 40µm cell strainer to achieve single cell 
suspension. After this process, the cells were ready for cell sorting. 
The cells were re-suspended in PBS containing 2% FCS and incubated with APC-Cy7 
conjugated mouse anti-human CD45 (557833, BD, 1:100), FITC conjugated mouse 
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anti-human CD34 (555821, BD, 1:100), BV711 conjugated mouse anti-human CD146 
(563186, BD, 1:100), PE-Cy7 conjugated mouse anti-human CD56 (557747, BD, 
1:100), Perpcp-Cy5.5 conjugated mouse anti-human CD144 (561566, BD, 1:100), 
APC conjugated mouse anti-human CD10 (655404, BD, 1:100), or CD107a (560664, 
BD, 1:100) antibodies on ice for 20 minutes in the dark. Fluorescence Minus One 
(FMO) and isotype-matched antibodies were used as negative controls. The cells were 
incubated with 4', 6-diamidino-2-phenylindole (DAPI, BD, 1:1000) for dead cell 
exclusion, and cell sorting was performed on a BDFACS Fusion flow cytometer. 
Compensation was calculated using single stain bead controls.  
The sorted cells were cultured and reanalysed by flow cytometry at passage 2, passage 
3, and passage 4 with the same combination of antibodies used for cell sorting. 
Mesenchymal stem cell markers were also assessed by flow analysis. Cultured cells 
were labelled at passage 3 and passage 4 with the following antibody: PECF 594 
conjugated mouse anti-human CD105 (562380, BD, 1:100), FITC conjugated mouse 
anti-human CD90 (555595, BD, 1:100), AlexaFluor700 conjugated mouse anti-
humanCD44 (561289, BD, 1:100), and Brilliant Violet 421 conjugated mouse anti-
human CD73 (562430, BD, 1:100). Isotype-matched antibodies were used. 
Cultured cells were used to purify pure populations of CD107a-positive and CD107-
negative when 3xT75 flasks were 70% confluent. The cells were detached by 0.25% 
trypsin-EDTA (GIBCO) for 10 minutes at 37℃, re-suspended in PBS/2% FCS, and 
then labelled with CD45-APC-Cy7, CD34-FITC, CD146-BV711, CD56-PE-Cy7, 
CD107a-APC, CD144-Percpcy5.5, CD105-PECF594, and CD73-Brilliant Violet 421. 
Cells were incubated with 7-amino-actinomycin D (7-AAD, 1:100, BD) for 10 minutes 
to exclude dead cells. FMO and isotype-matched antibodies were as negative controls. 
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2.3 Long-term cell culture and cell cryopreservation 
FACS-sorted perivascular cells were seeded at 5X103 cells per well (96 wells, Costar®) 
coated with 0.2% gelatin (Calbiochem) in Endothelial Cell Growth Medium 2 (EGM2, 
Cambrex BioScience) and cultured at 37℃ for one week. When the cells were 
confluent, they were detached using 0.25% trypsin-EDTA (GIBCO) for 10 minutes at 
37℃. The cells were then seeded in two wells of 12-well plates (Costar®). They were 
fed by DMEM with 20% FCS and 1%P/S (penicillin/streptomycin solution). The 
culture medium was refreshed twice a week. On the first passage, the cells were split 
into two groups; one half was treated with TRIzol® reagent for PCR analysis and the 
other half was seeded into six-well plates (Costar®). At confluence, one well of the 
six-well plate was harvested for flow analysis, one well was used for colony-forming 
unit–fibroblast (CFU-f) assay, and one well was passaged into two T75 flasks 
(Corning®). The remaining cells were frozen and stored at -80℃. The freezing 
medium contained 10% dimethyl sulfoxide in FCS. On the fourth passage, the cells 
were used for cell counting, differentiation, and flow analysis.  
2.4 Cell growth curves and doubling time 
At the third passage, when the cells reached 80% to 90% confluent, the cells were 
detached by 0.25% trypsin-EDTA and plated at a density of 5X104 cells/well in six-
well plates. After three, five, and seven days, cells from two wells were counted using 
a cell counting chamber using trypan blue solution (CORNING) for dead cell 




2.5 Colony-forming unit–fibroblast (CFU-f) assays 
For an in vitro perivascular stem cell colony assay, CFU-f assay was performed by 
plating 100 cells/well (cultured cells) or 500 cells/well (cell sorting) in culture medium 
in a six-well plate pre-coated with 0.1% gelatin. After 14 days, cells were fixed in 
methanol and stained with 0.5% Crystal Violet Solution. Colonies were defined as 
groups of more than 50 cells as detected using an imaging cytometer (Celigo).  
2.6 Adipogenic differentiation assay 
For in vitro adipogenic differentiation, 2X104 cells/well were seeded into 24-well 
plates and fed DMEM culture medium with 10% FCS and 1% P/S. When the cells 
reached 70% confluence, 10 wells of the 24-well plate were treated with differentiation 
medium DMEM with 10% FCS, 1 µM dexamethasone, 0.5 µM 
isobutylmethylxanthine, 60 µM indomethacin, and 170 µM insulin (all reagents from 
Sigma-Aldrich), and 10 wells were kept on the original medium as a control. For both 
conditions, the medium was changed twice weekly. After 14 days, five wells of cells 
from each condition were fixed using 4% PFA at room temperature, washed in 60% 
isopropanol, and incubated with 2ml/well Oil Red O (Sigma) working solution for five 
minutes to detect lipids. The remaining wells for each condition were treated with 
TRIzol® for PCR analysis. 
2.7 Osteogenic differentiation assay 
For in vitro osteogenic differentiation, 2X104 cells/well were seeded into 24-well 
plates, cells were fed DMEM culture medium with 10% FCS and 1% P/S. When the 
cells reached 70% confluence, 10 wells of the 24-well plate were treated with 
differentiation medium DMEM with 10% FCS, 0.1 µM dexamethasone, 10mM β-
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glycerophosphate, and 50 µg/ml ascorbic acid (all reagents from Sigma-Aldrich), and 
10 wells were kept on the original medium as a control. For both conditions, the 
medium was changed twice weekly. After 14 days, 10 wells cells were fixed in 4% 
PFA at room temperature. Mineralisation by osteoblasts was detected by Von Kossa 
staining [0.5% (w/v) silver nitrate, Sigma; 5% (w/v) sodium thiosulfate, Sigma]. Ten 
wells of cells were treated with TRIzol® for PCR analysis.  
2.8 Immunohistochemistry 
Fresh tissue samples were embedded in gelatin/sucrose and then gradually frozen by 
immersion in liquid nitrogen, after which the tissues were frozen at -80℃.  
For immunostaining, sections (7 um) were cut on a cryostat and subsequently fixed in 
acetone and methanol (1:1) on ice for 10 minutes before drying for 10 minutes at room 
temperature. Double staining was achieved by combining alkaline phosphatase (AP) 
(Fast Red Coloring) with 3, 3' diaminobenzidine (DAB) staining (Diaminobenzidine 
Coloring). 
For Fast Red Coloring: to block endogenous peroxidase/alkaline phosphatase, sections 
were blocked for 10 minutes in the block solution (Bloxall™, Vector), followed by 
blocking with normal 2.5% horse serum (Vector) for one hour at room temperature. 
The sections were then incubated with the primary antibody CD107a (36291401, 
Sigma) or CD10 (NBP1-47356, Novus) at 4℃ overnight. Primary antibodies were 
diluted 1:300 in phosphate-buffered saline (PBS) supplemented with 1% (w/v) bovine 
serum albumin (BSA). The next day, the sections were washed three times in PBS and 
then incubated with AP-conjugated secondary antibody (Vector, Anti-Rabbit Ig or 
Anti-Mouse Ig based on the primary antibody) for 30 minutes at room temperature. 
The sections were then washed once in PBS for five minutes and then in alkaline 
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phosphatase substrate (alkaline phosphatase substrate kit) until the sections presented 
a red colour. For DAB staining, the processes are the same as for alkaline phosphatase 
staining. After sections were blocked with normal 2.5% horse serum (Vector) for one 
hour at room temperature, the sections were incubated with primary antibody CD31 
(ab28364, Abcam or M0823, Dako) or CD146 (ab75769, Abcam) at 4℃ overnight. 
CD31 or CD146 was diluted in 1:100 in PBS supplemented with 1% BSA. The next 
day, the sections were washed three times in PBS and then incubated with hydrogen 
peroxide (HRP)-conjugated secondary antibody (Vector, Anti-Rabbit Ig or Anti-
Mouse Ig based on the primary antibody) for 30 minutes at room temperature. The 
sections were then washed once in PBS for five minutes and in then peroxidase 
substrate (peroxidase substrate kit) until the sections presented a brown colour. Finally, 
the sections were dehydrated for mounting onto slides. The sections were then ready 
for observing by microscopy (Zeiss or Olympus). 
2.9 Statistical analysis 
The statistical analyses were performed using the SPSS Statistics 21.0 software 
package to calculate the independent t-test for normally distributed data. Numbers or 
percentages were presented as mean ± standard deviation. P<0.05 was considered a 
significant difference. 




Chapter III: Results 
CD10 on perivascular stem cells 
3.1.1 Flow analysis and sorting 
CD10+/- subsets of PSCs were analysed in human placenta, human foetal muscle, 
human foetal brain, and adult adipose tissue. Table 1 shows that foetal muscle 
contained the highest percentage of CD10-positive adventitial cells, so we mainly 
focused on adventitial cells derived from human foetal muscle.  
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CD10 subsets of PSCs were sorted by FACS (Fig.1 & 2). Four foetal muscle samples 
were used (13-16 weeks), and the following observations were made: CD10-positive 
and negative adventitial stem cells expressed CD34 but not CD144 (excluding 
endothelial cells), CD56 (excluding myogenic cells), CD45 (excluding hematopoietic 
cells), and CD146. CD10-positive or -negative pericytes expressed CD146 but not 
CD144, CD56, CD45, and CD34. 
The population of CD10+, CD34+, CD56-, CD144-, and CD45- cells accounted for 
54.93% ± 18.48% of the total adventitial cells. CD10-, CD34+, CD146-, CD56-, 
CD144-, and CD45- cells amounted to 33.2% ± 15.97% of the total adventitial cells. 
CD10+, CD146+, CD56-, CD144-, and CD45- pericytes accounted for 8.3% ± 3.21% 
of the total pericytes, and CD10-, CD146+, CD34-, CD56-, CD144-, and CD45- cells 
for 85.0% ± 7.21% (Fig. 3). In summary, the percentage of CD10-positive adventitial 
cells is higher than that of CD10-negative adventitial cells. In contrast, CD10-negative 
pericytes are much more abundant than CD10-positive pericytes. 
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Human foetal muscle cells were processed to purify CD10 subsets of PSCs. A & B: Forward-scattered 
light (FSC) and side-scattered light (SSC) were used. C: DAPI was used to exclude dead cells and CD45 
to exclude hematopoietic cells. D: CD56 was used to exclude myogenic cells; CD144 was used to 
exclude endothelial cells. E: CD34 was used to identify adventitial cells (CD34+, CD146-, CD56-, 
CD144-, CD45-). CD146 was used to identify pericytes (CD34-, CD146+, CD56-, CD144-, CD45-). 
F&G: CD10 subsets of adventitial cells (CD10+, CD34+, CD146-, CD45-, CD144-, CD56- and CD10-
, CD34+, CD56-, CD45-, CD144-, CD56-) and CD10 subsets of pericytes (CD10+, CD146+, CD34-, 
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                CD10 adventitial cells 
Figure 2: Cell sorting shows distinct CD10 subsets of PSCs 
A: CD10 subsets of adventitial cells. B: CD10 subsets of pericytes 
 
                           
 
Figure 3: Distribution of CD10 subsets of perivascular stem cells in human foetal 
muscle. 
3.1.2 Cell culture 
Cultured CD10+/- PSCs are polygonal, and when cells become more than 80% 
confluent, they become elongated and spindle-shaped. There was no morphologic 























    
Figure 4: Morphology of perivascular stem cells in culture. 
A: CD10-positive adventitial cells. B: CD10-negative adventitial cells. C: CD10-positive pericytes. D: 
CD10-negative pericytes (5X104 cells were seeded; cells were cultured around day 5, 80% confluent). 
 
Growth curves and doubling times were described. Fig. 5 (A-B) shows that there was 
no obvious difference between CD10-positive and CD10-negative subsets of 
adventitial cells.                                                                                       




Figure 5 A-B: The proliferation of CD10 subsets of PSCs. 
A: Growth curve of CD10 subsets of adventitial cells. There was no great difference regarding 
proliferation potential. B: The doubling time was assessed online during days 3 to 5. There was no 
obvious difference between them. (Doubling time assessed using http://www.doubling-
time.com/compute.php.) 
3.1.3 Cultured CD10-negative adventitial cells give rise to CD10-
positive cells 
Culture cells (passage 2-4) were reanalysed by flow analysis using three human foetal 
muscle specimens. Neither CD10-positive nor CD10-negative adventitial cells express 




















































or CD56 (myogenic cells). Cells expressed CD146 (Fig. 6-7). CD10-negative 
adventitial cells that gave rise to CD10-positive cells from passage 2 to passage 4 (Fig. 
8).  
              
         
          
Figure 6: Adventitial cells do not express CD56, CD45, and CD144 in culture. 
 
In culture, CD10-positive and CD10-negative adventitial cells remain negative for 
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Figure 7: Both CD10-positive and CD10-negative adventitial cells were negative 
for CD34 expression but expressed CD146 in culture. 
 
 
      
 
Figure 8: 100% CD10-positive and CD10-negative adventitial cells expressed 
CD10 in culture. 
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3.1.4 Cultured CD10-negative and CD10-positive adventitial cells 
express mesenchymal stem cell markers 
At passage 3 (Fig. 9), both CD10-positive and CD10-negative adventitial cells 
expressed typical MSC markers: CD73, CD105, CD90, and CD44. Specifically, 
more than 90% of both CD10-negative and CD10-positive adventitial cells were 
shown to express CD44, CD90, CD73, and CD105. No difference was found 
between CD10-positive and CD10-negative adventitial cells in culture. This result 
further confirms that MSCs are derived from adventitial stem cells. Both CD10-
positive and CD10-negative adventitial stem cells showed osteogenesis 
differentiation potential in vitro. This also suggests that CD10 is a marker of 
mesenchymal stem cells. 
               
      
Figure 9: Both CD10-positive and CD10-negative adventitial cells express 














3.1.5 CFU-f assay  
Cultured CD10-positive and CD10-negative adventitial cells did not show a significant 
difference in the CFU-f assay (Fig. 10A-B). CD10-negative adventitial cells produced 
more colonies than CD10-positive adventitial cells.  
 
 
Figure 10 A-B: CD10 subsets of adventitial cells demonstrate CFU-f potential. 
A: For cultured cells, 100 cells were seeded in 2 wells of 6-well plates (duplicates). After 14 days, cells 
were stained using 0.5% Crystal Violet Solution. A colony contains more than 50 cells. Cultured CD10-
positive adventitial cells showed CFU-f potential similar to CD10-negative adventitial cells in 3 human 








































wells of 6-well plates (duplicates); CD10-negative adventitial cells formed more colonies in 2 human 
foetal muscle tissue specimens. Another foetal sample was excluded because there was no cells after 14 
days. 
3.1.6 Both CD10-positive and CD10-negative adventitial cells show 
osteogenesis potential 
To assess the differentiation potential of CD10 subsets of adventitial cells, both CD10-
positive and CD10-negative subsets underwent osteogenic differentiation in culture 
(Fig. 11). There was no distinct difference between CD10-positive and CD10-negative 
adventitial cells. 
 
                      
                      
Figure 11: CD10 subsets of adventitial cells in osteogenic differentiation. 
CD10-positive and negative adventitial cells cultivated in osteogenic medium for 14 days were fixed 
and probed for alkaline phosphatase before being incubated in a 0.5% silver nitrate solution [von 
Kossa staining; mineral deposits appear black (20x)]; cells cultivated in growth medium for 14 days 
and 0 days as controls. 
CD10-positive 
CD10-negative 
0 days     Growth medium  
          (14 days) 
 
Differentiation medium 
             (14 days) 
24 
 
3.1.7 Immuno-histochemical detection of CD10 in foetal muscle and 
heart 
To further confirm that CD10 PSC subsets exist in vivo, we investigated foetal heart 
and muscle tissues. We found that not all vessels express CD10 but that CD10 
expression is present in large and small vessels (Fig. 12).  
            
         
 
   
       











      
Figure 12: Detection of CD10 in human foetal muscle and heart. 
A & B: CD10 is expressed in large and small vessels in human foetal muscle. CD31 = brown staining; 
CD31 is expressed on endothelial cells. CD10 = red staining. C: CD10 is expressed in muscle fibres; 
large vessels are negative for CD10 in human foetal muscle. CD146 is shown in brown staining; CD10 
is shown in red staining. D: Isotype control in human foetal muscle. E–I: CD10 is expressed in small 
vessels. CD31 is shown in brown staining, CD31 is labelled on endothelial cells, and CD10 is shown in 
red staining. Blue arrow indicates CD10 staining around the vessel; red arrow indicates CD10-negative 
vessels. 
3.2 CD107a on perivascular stem cells 
3.2.1 Cell sorting 
CD107a subsets of perivascular stem cells were sorted by FACS; six foetal muscle 
samples were used. CD107a positive and negative adventitial stem cells expressed 
CD34 and were negative for CD144 (excluding endothelial cells), CD56 (excluding 
myogenic cells), CD45 (excluding hematopoietic cells), and CD146. CD107a positive 
or negative pericytes expressed CD146 but did not express CD144, CD56, CD45, or 
CD34. The population of CD107a+, CD34+, CD56-, CD144-, and CD45- cells 
accounted for 32.67% ± 29.25% of the total adventitial cells, whereas CD107a-, 
CD34+, CD146-, CD56-, CD144-, and CD45- cells amounted to 52.93%±30.91% of 
total adventitial cells. The population of CD107a+, CD146+, CD56-, CD144-, and 
CD45- cells accounted for 14.78% ± 15.91% of the total pericytes. CD107a-, CD146+, 
40x 
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40x 40x 
    H     I 
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CD34-, CD56-, CD144-, and CD45- amounted to 77.73% ± 20.91% of the total 
pericytes (Fig. 13). 
                              
 
                      
 
                                          
Figure 13: Isolating CD107a subsets of perivascular stem cells from human foetal 
muscle. 
Human foetal muscles were processed to purify CD107a PSC subsets. A & B: Forward-scattered light 
(FSC) and side-scattered light (SSC) were used to find viable single cells. C: DAPI was used to exclude 
dead cells and CD45 to exclude hematopoietic cells. D: CD56 was used to exclude myogenic cells and 
CD144 to exclude endothelial cells. E: CD34 was used to identify adventitial cells (CD34+, CD146-, 
CD56-, CD144-, CD45-). CD146 was used to identify pericytes (CD34-, CD146+, CD56-, CD144-, 
CD45-). F & G: CD107a subsets of adventitial cells CD107a+, CD34+, CD146-, CD45-, CD144-, 
CD56- and CD107a-, CD34+, CD56-, CD45-, CD144-, CD56-) and CD107a subsets of  pericytes 






































3.2.2 Cell culture 
Cultured CD107a subsets of perivascular cells were observed at passage 1-2 under 
microscopy (Zeiss) phase contrast. CD107a subsets of perivascular stem cells 
displayed polygonal morphology with short arms at 30% confluency. At 90% 
confluence, cells were spindle-shaped (Fig. 14). There was no significant 
morphological difference between CD107 subsets of PSCs. 
    
Figure 14: Morphology of CD107a perivascular stem cells. 
A: CD107a-positive adventitial cells. B: CD107a-negative adventitial cells (5x104 cells were seeded; 
pictures were taken after 3 days). C: CD107a-positive pericytes. D: CD107a-negative pericytes (5x104 
cells were seeded; pictures were taken after 5 days). 
Cell proliferation was compared using cell growth curves and doubling times (Fig. 
15A-B). There was no significant difference regarding proliferation between CD107a-
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Figure 15: Proliferation of CD107a subsets of adventitial cells (passage 3). 
A: There was no great difference in growth between CD107a-positive and negative adventitial cells 
(cells were counted at 3, 5, and 7 days in duplicate). B: Doubling time of CD107a-positive and CD107a-
negative adventitial cells, CD107a-negative adventitial cells showed shorter doubling time, but there 
was no great difference (doubling time assessed using http://www.doubling-time.com/compute.php). 
3.2.3 Flow cytometry analysis of cultured cells 
Cultured CD107a subsets of adventitial cells were reassessed using the same markers 
as used for cell sorting. No cells in culture expressed endothelial cell markers (CD144 
and CD31), hematopoietic cell markers (CD45), or myogenic cell markers (CD56) 
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but expressed CD146 (Fig. 18). CD107a subsets of adventitial stem cells gave rise to 
CD107a-positive and CD107a-negative cells in culture (Fig. 19). 
       
 
Figure 16: Both CD107a-positive and CD107a-negative adventitial cells were 
negative for CD56, CD45, and CD144 in culture. 
 
                           
Figure 17: Both CD107a-positive and CD107a-negative adventitial cells were 
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Figure 18: CD107a-positive and CD107a-negative adventitial cells were negative 
for CD34 but expressed CD146 in culture. 
                           
 
Figure 19: CD107a subsets of adventitial cells gave rise to CD107a-positive and 
CD107a-negative cells (n=3). 
Three human foetal muscle specimens were analysed for mesenchymal stem cell 
markers by flow cytometry (Fig. 20). We found that both CD107a-positive and 
CD107a 
CD107a 
    CD107a-positive 
CD107a 








CD107a-negative adventitial cells express CD105, CD44, CD73, and CD90 in culture. 
Additionally, CD107a-positive and CD107a-negative adventitial cells expressed the 
mesenchymal stem cell marker CD10 (Fig. 21) 
  
 
Figure 20: In culture, CD107a-positive and CD107a-negative adventitial cells 
express mesenchymal stem cell markers (CD44, CD90, CD73, & CD105). 
 
                           
     
Figure 21: In culture, CD107a-positive and CD107a-negative adventitial cells 
expressed the mesenchymal stem cell marker CD10. 
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3.2.4 Clonogenic potential of CD107a subsets 
The CFU-f assay was applied to show the potential of forming colonies in vitro. For 
cultured cells, the results show that CD107a-negative adventitial cells have a higher 
potential to form colonies in culture than CD107a-positive adventitial cells (p<0.05). 
For freshly sorted cells, there is no significant difference between CD107a-positive 
and CD107a-negative adventitial cells (Fig22A-B). 
 
 
Figure 22: CD107a-negative adventitial cells show high colony forming 
efficiency. 
3.2.5 Both CD107a-positive and CD107a-negative subsets of 
adventitial cells can differentiate into osteocytes and adipocytes 
To assess the differentiation potential of CD107a subsets of adventitial cells, both 
CD107a-positive and CD107a-negative adventitial cells were cultured in osteogenic 









































A: Cultured CD107a-negative and CD107a-positive adventitial cells were assessed using the CFU-
f test; CD107a-negative adventitial cells formed higher colony numbers compared to CD107a-
positive adventitial cells (3 human foetal muscle specimens were investigated). B: for fresh 
cells,after cell sorting, CD107a-negative adventitial cells formed colony numbers (2 human foetal 
muscle specimens were assessed. 
            A             B 
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osteogenic potential (p=0.049) compared to CD107a-negative adventitial cells, which 
showed poor capability for osteogenesis. 
Both CD107a-positive and CD107a-negative adventitial cells had the potential to form 
adipocytes (Fig. 24).CD107a-positive adventitial cells were prone to differentiate into 
adipocytes. 
 
                                    
   
                      
      
Figure 23: CD107a-positive adventitial cells show robust osteogenesis potential in 






































CD107a-positive adventitial cells formed more mineral deposits (black 10x; cells were cultured in 
growth medium as a control). 
 
                                
 
                                 
                                   
Figure 24: CD107a-positive adventitial cells show a high capability of adipogenic 
differentiation. 
Lipids are presented in red (10x). Cultured cells were further cultured in adipogenic medium for 14 
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3.2.6 Osteogenic potential of CD107a subsets re-sorted from cultured 
cells 
CD107a-positive and CD107a-negative adventitial cells were purified from foetal 
muscle. After 3-4 weeks, cultured cells were detached and CD107a-positive and 
CD107a-negative cells were re-sorted from each cultured cell population. 
The results show that CD107a-positive cells re-sorted from cultured CD107a-positive 
cells remained osteogenic differentiation, while, CD107a-negative cells re-sorted from 
cultured CD107a-negative cells remained resistant to osteogenesis (Fig. 25). 
                                                      
               
Figure 25: CD107a-positive adventitial cells show robust osteogenic 
differentiation potential in vitro. 
After cell sorting, CD107a-positive cells and CD107a-negative cells were isolated 
from cultured CD107a-positive and negative adventitial cells, respectively. CD107a-
positive adventitial cells differentiated into osteocytes, but CD107a negative cells 
failed to do so (3 human foetal tissues were assessed). 
3.2.7 Detection of CD107a in human tissues in situ 
To confirm the location of CD107a subsets of perivascular cells in situ, 
immunohistochemistry was applied to different tissues, including heart and muscle. As 
Fig. 26 shows, CD107a is expressed in most big vessels and some small vessels.  





                                                   
 
      
 
     
Figure 26: Detection CD107a in vessels in situ. 
A–F: CD107a is expressed in the vessels of foetal muscles. CD107a is shown in red, CD31 is shown 
in brown (endothelial cell staining). Yellow arrows represent CD107a-negative vessels. C: Isotype 
control staining. G–H: CD107a is expressed in large and small vessels in the foetal heart. CD107a-
negative vessels are indicated by yellow arrows; CD107a-positive vessels are indicated by blue 
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Chapter IV: Discussion 
The current study provides evidence that distinct PSC subsets exist in vivo and can 
be isolated from human foetal muscle based on CD10 or CD107a surface marker 
expression. The multiple properties of PSCs highlight the need for new markers to 
identify and purify PSC subsets. This is the first study investigating different subsets 
of perivascular stem cells based on the novel markers CD10 and CD107a. 
The study focuses on foetal muscle rather than other tissues (brain, placenta and adult 
fat). The main reason is that foetal muscle contains high percentage of CD10-positive 
PSC. Additionally, although fat contains high percentage of CD10-positive PSC, we 
found that the growth speed of CD10PSC was much slower than CD10 derived from 
foetal muscle in culture. Because time was limited, foetal muscle was studied. The 
study focuses on adventitial cells, and PSC was applied into the thesis because PSC 
includes adventitial cells and pericytes; therefore, the PSC in the thesis points to 
adventitial cells. 
CD10 was originally discovered and isolated from the kidney and has an enzymatic 
function to regulate differentiation [19]. CD10 is a potential biomarker for the 
diagnosis and prognosis of various tumours [32]. Furthermore, CD10 is a surface 
marker of tumour stem cells in multiple tissue types. CD10 is mainly involved in 
tumour proliferation, differentiation, and metastasis [33]. Recently, several studies 
have identified CD10-expressing mesenchymal stem cells derived from multiple 
human tissues, such as bone marrow, kidney, embryonic cartilage, and adipose tissue 
[19, 25, 34-35]. The current study provides evidence of CD10 expression on 
perivascular stem cells from human foetal muscle. Previous studies have found 
human umbilical cord mesenchymal stem cells in the perivascular area and that 
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100% of these cells express CD10 and possess contractile properties in culture [36]. 
Our group has demonstrated that mesenchymal stem cells are derived from 
perivascular stem cells [5]. The present study has provided evidence that CD10-
positive and CD10-negative perivascular stem cells exist in situ in the human foetal 
heart and muscle tissues. Furthermore, we confirmed that not all vessels expressed 
CD10 in situ; however, the study showed that CD10-negative cells can give rise to 
CD10-positive cells in culture, the precise reason for which is still unclear. 
Furthermore, we also tried to isolate CD10-positive and CD10-negative single cells, 
wherein CD10-negative cells still expressed CD10-positive in culture. We strongly 
suggest that the culture medium influences the phenotype of CD10 cells. Hagmann et 
al. report that different culture mediums significantly influence CD10 marker 
expression [38]. It requires further experiments to test how different mediums 
influence surface marker CD10 expression. Human bone marrow-derived 
mesenchymal stem cells express high amounts of CD10 during osteogenic and 
adipogenic differentiation [26]. Our results further confirmed that CD10-positive 
cells showed the potential of osteogenic differentiation. Both CD10-positive and 
CD10-negative cells expressed typical mesenchymal stem cell markers CD44.CD90, 
CD105 and CD73. It is further suggested that the progenitor of mesenchymal stem 
cells is a subset of PSC. Owing to CD10-negative cells giving rise to CD10-positive, 
we did not find any difference between CFU-f and osteogenic differentiation between 
CD10-positive and CD10-negative adventitial cells. Evidence shows that CD10 is 
involved in the differentiation of stem cells and cells signalling pathway [19], and it 




Overall, our results support the hypothesis that distinct functional perivascular stem 
cell subsets exist in vivo. We also confirm that progenitors of mesenchymal stem 
cells are located in the perivascular area and belong to PSCs. More work is needed to 
investigate the different functions of CD10-positive and CD10-negative perivascular 
stem cells. If the different functions of CD10-positive and CD10-negative PSC are 
explored, it will definitely indicate whether CD10-positive or CD10-negative PSC 
can be applied in treatment based on different situations. 
CD107a is widely used as a marker to identify natural killer cell activity [37]. Jensen 
et al. reported that CD107a and CD133 are co-expressed in tumour stem cells [30]. 
CD107a is also expressed in mesenchymal stem cells derived from bone marrow 
[30]. The authors also reported that full-length amelogenin can connect to the 
CD107a receptor to regulate the proliferation of mesenchymal stem cells. However, 
no studies have reported the function of CD107a in terms of CFU-f and 
differentiation potentials. We confirm that CD107a-positive and CD107-negative 
PSC subsets exist in situ in multiple human tissues by immunohistochemistry. 
Specifically, while CD107a-positive is expressed in big vessels and some small 
vessels, CD107a-negative is mainly expressed in small vessels. CD107a-positive and 
CD107a-negative PSC were cell-sorted from human foetal muscle. From CFU-f 
assays, we found that CD107a-negative adventitial cells showed higher CFU-f 
potential in culture. It suggested that CD107a-negative adventitial cells show high 
proliferation ability. Both CD107a-positive and CD107a negative adventitial cells 
expressed typical mesenchymal stem cells markersCD90, CD105, CD44 and CD73. 
However, cultured CD107a-positive adventitial cells demonstrated higher 
osteogenesis potential. CD107a adventitial cells gave rise to CD107a-positive and 
CD107a-negative cells in culture. We further purified CD107a subsets of adventitial 
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cells and investigated osteogenic differentiation potential, and found that CD107a-
positive adventitial cells show robust osteogenic differentiation potential. In contrast, 
CD107a-negative adventitial cells failed to do so. Our study demonstrated that there 
are distinct functional CD107a PSC subsets in vivo, CD107a-positive showed robust 
osteogenic and adipogenic differentiation. It requires further study to investigate the 
gene level of CD107a and explore if the level of CD107a increases during the 
osteogenic and adipogenic differentiation to understand the functions of CD107a. 
Given that there are few papers reporting the role of CD107a in mesenchymal stem 
cells, our results also provide evidence that it is important to further explore the role 
of CD107a in stem cells.  
Overall, this work suggests that CD107a-positive cells present mesenchymal stem 
cell properties. 
In conclusion, we support the hypothesis that there are distinct functional 
perivascular stem cell subsets in vivo. This is the first study of perivascular stem cells 
subsets based on novel markers CD10 and CD107a. Our study showed the promising 
resource of CD10 PSC or CD107a PSC for regeneration medicine. The current study 
focused on CD10 or CD107a adventitial cells. However, future studies will be 




Chapter V: Conclusion & Limitations 
5.1 Conclusion 
The findings of the current research provide insight into PSC subsets typified using 
the novel markers CD10 and CD107a. We have demonstrated that CD10 or CD107a 
PSC subsets exist in human foetal tissues. We also purified and identified the subsets 
of perivascular stem cells by flow cytometry. CD10 subsets of perivascular stem cells 
presented the characteristics of mesenchymal stem cells in vitro. For CD107a subsets 
of perivascular stem cells, we provide evidence that CD107a-positive and CD107a-
negative PSCs exist in vivo. In vitro, CD107a-positive adventitial cells have robust 
osteogenic differentiation potential. Therefore, CD107a-positive and CD107a-
negative cells represent two subsets of perivascular stem cells. This is the first time 
that it has been reported that CD107a positive subsets of perivascular stem cells 
showed robust osteogenic differentiation potential. Therefore, it may be necessary to 
separate distinct functional subsets to optimize the application of perivascular stem 
cells in the field of regenerative medicine. Overall, this study supports our hypothesis 
that distinct functional subsets exist in vivo.  
5.2 Limitations 
There are two main limitations to this study: first, more samples are needed to 
confirm current results. Second, currently, our studies are performed in vitro. In 
future studies, we need to test whether subsets of perivascular stem cells show 
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